Author:
Bocquet-Tremoureux Solène,Scharbarg Emeric,Nguyen Jean-Michel,Varey Emilie,Quereux Gaëlle,Saint-Jean Melanie,Peuvrel Lucie,Khammari Amir,Dreno Brigitte
Reference18 articles.
1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–64.
2. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23.
3. Wiater K, Switaj T, Mackiewicz J, et al. Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. Contemp Oncol Poznan Pol 2013; 17: 257–62.
4. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of longterm survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33: 1889–94.
5. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010; 37: 473–84.